-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On January 7, Qilu submitted an application for 4 types of generic octreotide acetate microspheres for injection, which is expected to hit the first domestic imitation
.
The original research company of the microsphere preparation is Novartis.
In 2020, the terminal sales in China's public medical institutions will exceed 400 million yuan.
Changchun Jinsai Pharmaceutical and Livzon Group have been approved for clinical use
.
.
The original research company of the microsphere preparation is Novartis.
In 2020, the terminal sales in China's public medical institutions will exceed 400 million yuan.
Changchun Jinsai Pharmaceutical and Livzon Group have been approved for clinical use
.
Figure 1: The latest products declared by Qilu
Source: CDE official website
Figure 2: Sales of octreotide acetate microspheres for injection (unit: ten thousand yuan)
Source: Minet.
com China's public medical institutions terminal competition pattern
com China's public medical institutions terminal competition pattern
Octreotide acetate microspheres for injection are long-acting injections of octreotide, which only need to be administered once a month, and are the first choice forthe treatment of acromegaly and gastroenteropancreatic neuroendocrine tumors
.
Novartis' original research drug entered the Chinese market in 2003, and there are no generic drugs listed in China.
According to Minet.
com data, in 2020, there will be public hospitals in China , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions).
) terminal, the sales of original research drugs have exceeded 400 million yuan, and the growth rate in 2020 is still as high as 88% under the influence of the epidemic, and the market potential should not be underestimated
.
.
Novartis' original research drug entered the Chinese market in 2003, and there are no generic drugs listed in China.
According to Minet.
com data, in 2020, there will be public hospitals in China , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions).
) terminal, the sales of original research drugs have exceeded 400 million yuan, and the growth rate in 2020 is still as high as 88% under the influence of the epidemic, and the market potential should not be underestimated
.
Figure 3: Clinical progress related to octreotide acetate microspheres for injection
Source: Minet China Drug Clinical Trials Publicity Library
Changchun Jinsai Pharmaceutical obtained clinical approval in 2017, and Phase I clinical trials are currently underway; Livzon Group will report production in 2020, and then obtain clinical approval; Qilu completed BE in 2021, and is now applying for listing, depending on the progress Look, winning the first copy is a high probability event
.
.
In recent years, Qilu has made great efforts in the field of new formulations, and has gradually built a research and development and production platform for new formulations such as microspheres, nanoparticles, oral dissolving films, and soft capsules, and realized the industrialization of many scientific research results
.
.
Taking the oral dissolving pipeline as an example, Qilu has obtained the production approvals for olanzapine oral dissolving film, montelukast sodium oral dissolving film, aripiprazole oral dissolving film, tadalafil oral dissolving film, and methicillin hydrochloride.
The King Kong oral dissolving film is being reported for production.
In addition, the clinical approvals for escitalopram oxalate oral dissolving film, risperidone oral dissolving film and vardenafil hydrochloride oral dissolving film are also in its capsule
.
The application for listing of octreotide acetate microspheres for injection is a solid step taken by the company in the microsphere preparation pipeline
.
The King Kong oral dissolving film is being reported for production.
In addition, the clinical approvals for escitalopram oxalate oral dissolving film, risperidone oral dissolving film and vardenafil hydrochloride oral dissolving film are also in its capsule
.
The application for listing of octreotide acetate microspheres for injection is a solid step taken by the company in the microsphere preparation pipeline
.
Source: Minet database, CDE official website
The statistics of clinical data are as of January 6.
If there are any mistakes or omissions, please correct me
.
If there are any mistakes or omissions, please correct me
.
On January 7, Qilu submitted an application for 4 types of generic octreotide acetate microspheres for injection, which is expected to hit the first domestic imitation
.
The original research company of the microsphere preparation is Novartis.
In 2020, the terminal sales in China's public medical institutions will exceed 400 million yuan.
Changchun Jinsai Pharmaceutical and Livzon Group have been approved for clinical use
.
.
The original research company of the microsphere preparation is Novartis.
In 2020, the terminal sales in China's public medical institutions will exceed 400 million yuan.
Changchun Jinsai Pharmaceutical and Livzon Group have been approved for clinical use
.
Figure 1: The latest products declared by Qilu
Source: CDE official website
Figure 2: Sales of octreotide acetate microspheres for injection (unit: ten thousand yuan)
Source: Minet.
com China's public medical institutions terminal competition pattern
com China's public medical institutions terminal competition pattern
Octreotide acetate microspheres for injection are long-acting injections of octreotide, which only need to be administered once a month, and are the first choice for the treatment of acromegaly and gastroenteropancreatic neuroendocrine tumors
.
Novartis' original research drug entered the Chinese market in 2003, and there are no generic drugs listed in China.
According to Minet.
com data, in 2020, there will be public hospitals in China , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions).
) terminal, the sales of original research drugs have exceeded 400 million yuan, and the growth rate in 2020 is still as high as 88% under the influence of the epidemic, and the market potential should not be underestimated
.
.
Novartis' original research drug entered the Chinese market in 2003, and there are no generic drugs listed in China.
According to Minet.
com data, in 2020, there will be public hospitals in China , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions).
) terminal, the sales of original research drugs have exceeded 400 million yuan, and the growth rate in 2020 is still as high as 88% under the influence of the epidemic, and the market potential should not be underestimated
.
Figure 3: Clinical progress related to octreotide acetate microspheres for injection
Source: Minet China Drug Clinical Trials Publicity Library
Changchun Jinsai Pharmaceutical obtained clinical approval in 2017, and Phase I clinical trials are currently underway; Livzon Group will report production in 2020, and then obtain clinical approval; Qilu completed BE in 2021, and is now applying for listing, depending on the progress Look, winning the first copy is a high probability event
.
.
In recent years, Qilu has made great efforts in the field of new formulations, and has gradually built a research and development and production platform for new formulations such as microspheres, nanoparticles, oral dissolving films, and soft capsules, and realized the industrialization of many scientific research results
.
.
Taking the oral dissolving pipeline as an example, Qilu has obtained the production approvals for olanzapine oral dissolving film, montelukast sodium oral dissolving film, aripiprazole oral dissolving film, tadalafil oral dissolving film, and methicillin hydrochloride.
The King Kong oral dissolving film is being reported for production.
In addition, the clinical approvals for escitalopram oxalate oral dissolving film, risperidone oral dissolving film and vardenafil hydrochloride oral dissolving film are also in its capsule
.
The application for listing of octreotide acetate microspheres for injection is a solid step taken by the company in the microsphere preparation pipeline
.
The King Kong oral dissolving film is being reported for production.
In addition, the clinical approvals for escitalopram oxalate oral dissolving film, risperidone oral dissolving film and vardenafil hydrochloride oral dissolving film are also in its capsule
.
The application for listing of octreotide acetate microspheres for injection is a solid step taken by the company in the microsphere preparation pipeline
.
Source: Minet database, CDE official website
The statistics of clinical data are as of January 6.
If there are any mistakes or omissions, please correct me
.
If there are any mistakes or omissions, please correct me
.
On January 7, Qilu submitted an application for 4 types of generic octreotide acetate microspheres for injection, which is expected to hit the first domestic imitation
.
The original research company of the microsphere preparation is Novartis.
In 2020, the terminal sales in China's public medical institutions will exceed 400 million yuan.
Changchun Jinsai Pharmaceutical and Livzon Group have been approved for clinical use
.
.
The original research company of the microsphere preparation is Novartis.
In 2020, the terminal sales in China's public medical institutions will exceed 400 million yuan.
Changchun Jinsai Pharmaceutical and Livzon Group have been approved for clinical use
.
Figure 1: The latest products declared by Qilu
Source: CDE official website
Figure 2: Sales of octreotide acetate microspheres for injection (unit: ten thousand yuan)
Source: Minet.
com China's public medical institutions terminal competition pattern
com China's public medical institutions terminal competition pattern
Octreotide acetate microspheres for injection are long-acting injections of octreotide, which only need to be administered once a month, and are the first choice for the treatment of acromegaly and gastroenteropancreatic neuroendocrine tumors
.
Novartis' original research drug entered the Chinese market in 2003, and there are no generic drugs listed in China.
According to Minet.
com data, in 2020, there will be public hospitals in China , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions).
) terminal, the sales of original research drugs have exceeded 400 million yuan, and the growth rate in 2020 is still as high as 88% under the influence of the epidemic, and the market potential should not be underestimated
.
Cancer Cancer Hospital Hospital Hospital_.
Novartis' original research drug entered the Chinese market in 2003, and there are no generic drugs listed in China.
According to Minet.
com data, in 2020, there will be public hospitals in China , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions).
) terminal, the sales of original research drugs have exceeded 400 million yuan, and the growth rate in 2020 is still as high as 88% under the influence of the epidemic, and the market potential should not be underestimated
.
Figure 3: Clinical progress related to octreotide acetate microspheres for injection
Source: Minet China Drug Clinical Trials Publicity Library
Changchun Jinsai Pharmaceutical obtained clinical approval in 2017, and Phase I clinical trials are currently underway; Livzon Group will report production in 2020, and then obtain clinical approval; Qilu completed BE in 2021, and is now applying for listing, depending on the progress Look, winning the first copy is a high probability event
.
.
In recent years, Qilu has made great efforts in the field of new formulations, and has gradually built a research and development and production platform for new formulations such as microspheres, nanoparticles, oral dissolving films, and soft capsules, and realized the industrialization of many scientific research results
.
.
Taking the oral dissolving pipeline as an example, Qilu has obtained the production approvals for olanzapine oral dissolving film, montelukast sodium oral dissolving film, aripiprazole oral dissolving film, tadalafil oral dissolving film, and methicillin hydrochloride.
The King Kong oral dissolving film is being reported for production.
In addition, the clinical approvals for escitalopram oxalate oral dissolving film, risperidone oral dissolving film and vardenafil hydrochloride oral dissolving film are also in its capsule
.
The application for listing of octreotide acetate microspheres for injection is a solid step taken by the company in the microsphere preparation pipeline
.
The King Kong oral dissolving film is being reported for production.
In addition, the clinical approvals for escitalopram oxalate oral dissolving film, risperidone oral dissolving film and vardenafil hydrochloride oral dissolving film are also in its capsule
.
The application for listing of octreotide acetate microspheres for injection is a solid step taken by the company in the microsphere preparation pipeline
.
Source: Minet database, CDE official website
The statistics of clinical data are as of January 6.
If there are any mistakes or omissions, please correct me
.
If there are any mistakes or omissions, please correct me
.
